Santhera Collaborating With Swiss Researchers to Develop New Gene Therapy for LAMA2 MD

Santhera Collaborating With Swiss Researchers to Develop New Gene Therapy for LAMA2 MD

Santhera Pharmaceuticals has entered into a collaboration agreement with researchers from the Biozentrum of the University of Basel in Switzerland to develop a new gene therapy for treating people with LAMA2-deficient congenital muscular dystrophy (LAMA2 MD).

LAMA2 MD, also known as merosin-deficient congenital muscular dystrophy (MDC1A), is a type of muscular dystrophy caused by genetic mutations in the LAMA2 gene. This gene provides instructions to make a protein called laminin-alpha 2, which is one of the proteins required to build muscle fibers.

Gene therapy is one of the most promising therapeutic avenues for people with inherited disorders, including those with different types of muscular dystrophy.

The new $1.21 million research collaboration between Santhera and Markus Rüegg, PhD, professor of neurobiology at the Biozentrum of the University of Basel, aims at supporting the development of a novel gene therapy for the treatment of LAMA2 MD.

The therapy, developed by Rüegg and collaborators, is based on the production of two small protein fragments, called linker proteins, derived from other extracellular matrix proteins. These linker proteins have been designed to restore the structure and function of muscle fibers lacking laminin-alpha 2. The extracellular matrix is the network that surrounds and supports cells as they grow.

Connect with other people and share tips on how to manage Muscular Dystrophy in our forums!

In animal models of LAMA2 MD, researchers have shown that linker proteins successfully restored the structure and function of muscle fibers, leading to a significant increase in the animals’ body weight and lifespan. They are now hopeful the same thing can be achieved in human patients.

“LAMA2 MD is a severe form of congenital muscular dystrophy (CMD) which based on its molecular pathology [mechanisms of disease] offers the possibility for gene replacement,” Rüegg said in a press release.

“The approach we have optimized over the past years relies on the simultaneous expression of two linker proteins engineered from extracellular matrix proteins. We and others have shown that this approach has a profound beneficial effect in mouse models of the disease. I am looking forward to collaborating with Santhera as our translational research partner to advance our gene therapy approach towards clinical use,” Rüegg added.

The collaboration agreement also will assess whether gene delivery using conventional viral vectors might be feasible in human patients participating in future clinical studies.

The project is supported by public funds aimed at promoting scientific innovation in Switzerland through a grant from Innosuisse – the Suisse Innovation Agency. Santhera and Innosuisse will invest a total of CHF 1.2 million (US$1.21 million) to support the costs of the research collaboration.

“We are excited to collaborate with experts from the Biozentrum to advance this novel gene therapy approach to the clinic for the benefit of patients with this devastating disease,” said Thomas Meier, PhD, CEO of Santhera.

“We build on our experience with omigapil, which we have recently studied in a Phase 1 clinical trial [NCT01805024] in patients with CMD in a collaboration with experts at the National Institutes of Health (USA). From our previous work we anticipate that this novel gene therapy approach and omigapil could act complementary. As before, we will continue working closely with clinical experts and the patient community to establish the best way forward,” he added.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.
×
Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • Adult Certified Duchenne Care Center
  • vamorolone extension study
  • trial
  • vamorolone extension study
Average Rating
0 out of 5 stars. 0 votes.
My Rating:

9 comments

  1. Izzy says:

    Hi, I’m in the US and have an 12mth old boy we would like to be in the trial please. 🙏🏼 Thank you for all that you do.

  2. Marina says:

    We are from Russia. My daughter is 4 years old. We look forward to the start of clinical trials. I will be happy if my daughter enters the clinical trials.

  3. Yusuf says:

    Hello,
    My father is fighting with inclusion body myopsis. Will this therapy work for him?
    Many thanks for all your efforts.

  4. maka kobakhidze-Oniani says:

    hello, our doughter, 30 yars old, has autosomal recessive merosin deficient CMD, variant NM_000426.3:c.6955C.>T, Exon 49, Het. + NM_000426.3:c.1169G>A, Exon 8, Het. We are looking for optimal genetig therapy, Please, halp us, as it is possible.

Leave a Comment

Your email address will not be published. Required fields are marked *